# HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

> **NCT06364007** · PHASE2 · UNKNOWN · sponsor: **Sulai Liu** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** HAIC+STRIDE+Len

## Key facts

- **NCT ID:** NCT06364007
- **Lead sponsor:** Sulai Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-03
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364007, "HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06364007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*